Objective :L iver cirrhosis is characterized by reduced circulating IGF-I and this has been linked to an adverse clinical outcome.Therefore, we investigated the dynamic changes in circulating total, free, and bioactiveI GF-I, IGF-binding protein (IGFBP)-1, IGFBP-2, and IGFBP-1-bound IGF-I (binarycomplex) during an oral glucose tolerance test (OGTT) in patients with liver cirrhosis. Methods:Seven Caucasian males with liver cirrhosis and seven healthymales matched for age (54.4G 3.2 vs 54.6G 4.4 years) and body mass index( 25.3G 1.2 vs 25.9G 1.3 kg/m 2 )w ere studied. Blood samples were drawn at 0, 30, 60, 90, 120, 150, and 180 min for determination of serum total and free IGF-I, IGFBP-1, IGFBP-2, and binarycomplex, while bioactiveIGF-I wasmeasured at 0, 30, 60, 120, and 180 min. Results:Incomparison with healthysubjects, baseline levels of total (47%), free (36%), and bioactive IGF-I (51%) were lower,w hile IGFBP-1 (268%) wash igher ( P ! 0.05), IGFBP-2 (172%) tended to be higher ( P O 0.05), and the binarycomplexunchanged ( w 100%) in cirrhotic patients. Serum total and free IGF-I, and IGFBP-2 remained unchangedinb oth study groups during the OGTT.B ioactiveIGF-I decreased by 29% from baseline to 60 min in cirrhotic patients and remained low at the end of the OGTT ( P ! 0.05). As imilar tendency waso bservedi nh ealthyc ontrols ( P Z 0.052). Concomitantly, IGFBP-1, binarycomplex, and IGFBP-1 saturation indexd ecreased significantlyi nb oth groups. The disappearance of the binarycomplex wasa bout twofold faster than that of IGFBP-1 ( P ! 0.05). Conclusion:D espite unchangedc oncentrations of total and free IGF-I, bioactive IGF-I declined significantlya fter an oral glucose load in patients with liverc irrhosis and the same tendency was observedinhealthysubjects. We speculate that the reduction in bioactiveIGF-I mayberelated to the higher levels of free IGFBP-1 and the faster disappearance of IGFBP-1-bound IGF-I. 155 285-292 
Introduction
The insulin-like growth factor (IGF) superfamilyconsists of twop rimaryl igands, IGF-I and IGF-II, at least three different receptors, six specifichigh-affinity IGF-binding proteins (IGFBPs) and an on-IGF-binding peptide -t he acid labile subunit (1).D ue to its participation in numerous physiological and pathophysiological processes (2-4),I GF-I is considered the most important member of this superfamily. It is generallybelieved that IGF-I bioactivity is maintainedp rimarily through free, unbound IGF-I (5, 6).Therefore,the inverseassociation between the circulatingconcentrations of free IGF-I and IGFBP-1, whichh as been demonstrated in healthy subjects (7, 8) , suggests thatI GFBP-1 is ap otent inhibitor of IGF-I-mediated biological effects in vivo , mostlikelyb yr egulating the levels of free IGF-I (1, 9).
Circulating IGF-I and IGFBP-1 are both synthesized predominantlyinthe liver under the control of various hormones (10) (11) (12) (13) (14) , and accordingly,c hronicl iver disease has ap rofound impact on the plasma concentrations of IGF-I and IGFBP-1. Indeed, in comparison to healthysubjects, increasedcirculating levels of IGFBP-1, but lower total and free IGF-I, are characteristic features of liver cirrhosis (15) (16) (17) (18) (19) . Furthermore, one of the major health problems in cirrhotic patients is malnutrition, whichexertsaserious adverse effect on clinical outcome. Althought he pathophysiology of malnutrition in cirrhosis is complex, there is as olid evidence thatp atients with cirrhosis suffer from both growth hormone (GH)r esistance and ar educed ability to synthesizeIGF-I, the major downstream effector peptide of GH (20, 21) .Itisverylikelythatthese abnormalities mayb er elated to and partlye xplain the relatively highm orbidity and mortality in patients with liver cirrhosis (22) .
Moreover, it is well recognized that most cirrhotic patients are intolerant of oral glucose,evenw hen their fasting blood glucose concentrationsa re normal (23, 24) .T his appearst ob et he result of impaired insulin secretion and insulin sensitivity (25) .Asaconsequence of reduced hepatic IGF-I-producing capacity,e levated IGFBP-1,a nd loweri nsulin sensitivity, it mayb e anticipated that in patientsw ith liver cirrhosis, the responsiveness of the IGF system to an oral glucose challenge mayb ed ifferent from thatf ound in normal healthys ubjects (19, 26) .H owever,s uchs tudies have not yetb een performed. Therefore, the objectiveo ft he present study wast oc ompare the dynamicc hanges in circulatingtotal, free, and bioactiveIGF-I, and IGFBP-1 during an oral glucose tolerance test (OGTT)inpatients with liver cirrhosis and healthycontrols.
Subjects and methods

Subjects
The study protocolw as approved by the local ethics committee andc onducted in accordancew itht he Declaration of Helsinki. Written informed consentw as obtained from all patients and controls before initiating anyt rial-related activity.
Seven Caucasian males with liver cirrhosis and seven healthym ales matchedf or age (54.4G 3.2 vs 54.6G 4.4 years) and body massi ndex (25.3G 1.2 vs 25.9G 1.3 kg/m 2 )w ere studied.Liver biopsies were performed in all cirrhotic subjects, whow ere class Ba ccordingt o the Child-Pugh classification. Six of the patients were diagnosed with alcoholic cirrhosis ando ne with primaryb iliaryc irrhosis. Ad etailed biochemical description of these patientsa nd their glucose homeostatic condition has been published previously ( 25) . All patients receiving diuretics or other medications knownt oa ffect carbohydrate metabolismw ere instructed to discontinue the medication at least 48 h before the study.All study subjectswere in good health, had normal bloodp ressure, and were at stable weight. Nonehad afamilyhistoryofdiabetesamong first-degree relatives. The subjects were instructed not to engagein vigorous exercise at least 3daysp rior to study.
Experimental protocol
Following an overnight fast, study subjects were admitted to the general clinicalr esearch centre at 0800h.A ni .v.c annula wasi nserted into an antecubital vein for bloods ampling. After ingestion of 75 g glucose over 1min,blood samples were drawn at 0, 30, 60, 90, 120, 150,a nd 180 min for determination of serum concentrationso ft otala nd free IGF-I, IGFBP-1, IGFBP-2, and IGF-I:IGFBP-1 binaryc omplex, while bioactiveI GF-1 wasm easured at 0, 30, 60, 120, and 180 min.
Assays
All blood samples were centrifuged immediatelyat48 C and stored at K 20 8 Cuntil analysis.
Serum total (extractable) IGF-I wasdetermined by an in-house time-resolved immunofluorometric assay(TR-IFMA) in acid-ethanolserum extracts, with within and between assayc oefficient of variation (CV) values averagingl esst han5and1 0% respectively (27) . Serum free IGF-I wasd etermined after ultrafiltration by centrifugation at conditions approachingt hose of in vivo (6).T he within and between assayC Vv alues averaged 15 and 20%.
Serum bioactive IGF-I wasm easured by an IGF-I kinase receptor activation assay( KIRA), which was basedo nh uman IGF-I receptor gene-transfected cells (human embryonic renal cells, EBNA2 93; Invitrogen) (28) . In brief, cultured cells were stimulated at 37 8 C with either IGF-I standards (a serial dilutionr anging from 0.3 to 5 m g/l of recombinant human IGF-I (Austral Biologicals, San Ramon, CA,U SA)) or serum-diluted 1:10inKrebs Ringer buffer.After 15 min, samples were removed and the cells lysed. Crude cell lysates were then transferred to an assaythat detects the concentration of phosphorylated (i.e. activated) IGF-I receptors. This assayu sesaM AB against the extracellular domain of the IGF-I receptor for coating and ae uropium-labeled monoclonal anti-phosphotyrosine antibody( PY20)a s tracer.The IGF-I bioassayw as sensitive(detection limit 0.08 m g/l),s pecific( cross-reactivity of insulin, rapidacting insulin analogs, and pro-insulin were less than 1%;I GF-II cross-reactivity was1 2%), and accurate (within and between assayC Vv alues were less than 7 and 15% respectively).
Serum IGFBP-1 wasassessed by an in-house RIA and IGFBP-2 by an in-house TR-IFMA as previously described (29) . Mean within and between assayC V values were less than 6and 12% respectively. IGFBP-1-associated IGF-I (binarycomplexofIGF-I and IGFBP-1) wasd etermined by an in-house TR-IFMA using an IGFBP-1 antibodyf or coating,a nd ae uropium-labeled IGF-I antibodyastracer.The within and between assay CV values of them easurement were 5a nd 15% respectively(9).
Statistical analysis
To improve the distributiono fo ur data, all continuous variables were logarithmically(ln) transformedpriort o the statistical analysis.A tb aseline( time 0), differences between cirrhotic patients and healthyc ontrolsw ere compared by Student'sunpaired t -test. Linear regression analysis wasalso used to estimatecorrelations between parameters.D uringt he OGTT,p arametersw ere compared by ANOVA for repeated-measures or one-way ANOVAfollowed by post hoc multiple comparisons (least significantdifference), whenever necessary. Results were expressed as untransformed meansG S . E . M ., except where stated. Furthermore, the area under the time-concentration curves( AUCs) have been calculated usingt he trapezoidal rule. The AUCs of the twog roups werecompared by Student'su npaired t -test. Statistical analyses were performed using SPSS 11.0 for Windows (SPSS, Chicago, IL, USA). P valueso f5 %o rl ess were considered significant.
Results
Glucose and insulin
The glucose-metabolicp rofile of the participants has been investigated thoroughly, and has been published elsewhere (25) .I nb rief, the cirrhotic patients had a normal fastingg lucose,b ut approximatelyt wofold elevated fastingl evelso fi nsulin andC -peptide ( P ! 0.05). During the OGTT,c irrhotic patients were shown to be glucose intolerant (the 2-h value averaged 8.5G 1.0 vs 6.7G 0.9 mmol/l (patients versus controls), P ! 0.05) and insulin resistantw ith higher levels of insulin andC -peptidet hroughout the OGTT as compared with controls( for furtheri nformation, see reference (25) ).
Baseline levels
At baseline, plasma concentrationso ft otal, free, and bioactiveIGF-I were significantlylower in patients with liverc irrhosis as comparedw ith healthys ubjects ( P ! 0.05, Table 1 ).I nc ontrast, the circulating level of IGFBP-1 was higheri np atients than in controls. Furthermore, the fasting levels of IGFBP-2 and IGF-I:IGFBP-1 binaryc omplex were numericallyh igher in cirrhotic patients, but the differencesd id not reach statistical significance ( P Z 0.07 and 0.2 respectively, Table 1 ).
To evaluate the relationship betweend ifferent parametersa tb aseline, as tepwise linear regression analysis wase mployed with bioactiveI GF-I as the dependent variable versus total and free IGF-I as the independentvariables.This showed that bioactiveIGF-I wassignificantlyand positivelypredicated by the serum concentration of free IGF-I (slopeZ 2.65G 0.63 m g/l, r 2 Z 0.59, P ! 0.01). Thiss trong association remained significantafter adjusting for IGFBP-1 and IGF-I:IGFBP1b inaryc omplex. The correlation between bioactive and free IGF-I wasm ainlyd riven by the patient group (cirrhotic patients: slope Z 4.37G 0.85 m g/l, r 2 Z 0.84, P ! 0.01; control subjects: slopeZ 3.28G 2.19 m g/l, r 2 Z 0.31, P O 0.05). Furthermore, free and bioactive IGF-Iw eren egatively correlated withI GFBP-1 ( r 2 Z 0.49 and 0.31r espectively, P ! 0.05). There was no statisticallys ignificantc orrelation between free or bioactiveIGF-I and binarycomplex.
Changes during OGTT
In comparison with baseline, the plasma concentrations of totala nd free IGF-I did not change significantlyi n either cirrhoticp atientso rh ealthy controls after ingestion of 75 gglucose ( Fig. 1A and B) .
Serum IGF-I bioactivity decreased significantlyb y 24G 0.1% ( P ! 0.05) from 0. (Fig. 2A) . In healthycontrols, the levels of IGFBP-1 were significantlyd ecreased by 19-41% ( P ! 0.01) from 34.2 G 2.9 m g/l at baseline to 27.8G 2.5 m g/l at 90 min, 23.7G 2.1 m g/l at 120 min, 21.6G 1.9 m g/l at 150 min,and 20.1 G 2.7 m g/l at 180 min respectively.
During the OGTT,s erum levels of the IGF-I:IGFBP-1 binaryc omplexd ecreased significantlyb y4 4-59%i n cirrhotic patients from 16.2 G 3.1 m g/l at baselinet o 9.0G 1.8 m g/l at 90 min, 6.9G 1.6 m g/l at 120 min, 6.9 G 1.5 m g/l at 150min,a nd 6.6 G 1.3 m g/l at 180 min (Fig.2B) . In healthysubjects, the reduction in binarycomplex from baseline (11.5G 2.8 m g/l) appeared or tended to be statistically significanta t1 20 min (5.4G 0.9 m g/l, P ! 0.01), 150min (4.5G 0.8 m g/l, P Z 0.058), and 180 min (3.8G 0.9 m g/l, P ! 0.01).
The IGFBP-1 saturation index wasc alculated as the molar ratioofIGF-I:IGFBP-1 binarycomplextoIGFBP-1 and it servesa sa ne stimate of the fraction of 'free IGFBP-1' (9).Ingeneral, the index tended to be lower in patients with cirrhosis as comparedw ithc ontrol subjects (Fig.2 C) , but the differences were not www.eje-online.org statisticallys ignificant. In cirrhotic patients, the index wasr educed from 24G 6% at baseline to 20G 5% at 30 min after the glucose challenge ( P O 0.05). The reductions from baseline reached statistical significance ( P ! 0.05) at 90 min (17G 5%), 120 min (14G 4%), 150 min (15G 4%), and 180 min (15G 4%) respectively. In healthys ubjects, the decrease in IGFBP-1 saturation index commenced at 90 min (baseline versus 90, 120, 150, and 180 min: 32G 6v s2 8 G 32 2 G 3, 21G 4, and 18G 2%), being statisticallys ignificant at 120 and 180 min only( P ! 0.05). The time-concentration curveso fI GFBP-1 and the binaryc omplex (Fig.2 Aa nd B) impliedt hatt he clearance of IGFBP-1-bound IGF-I might be faster thant hat of IGFBP-1. Therefore, the half-life ( T 1/2 )f or each individual wasc alculated by linear regression analysis after ln-transformation of rawd ata, using the ratiobetween ln (2) and the slope of the regressionline as an estimate of T 1/2 .T he T 1/2 of IGFBP-1a veraged 212G 13 min in healthycontrols and 310G 99 min in cirrhotic patients. The larger variation in the patient groupwas caused by one subject ( T 1/2 Z 876 min), who wasomitted from the final analysis. The T 1/2 of IGFBP-1 was2 16G 32 min in the remaining six patients, and this wass imilar to thatofthe controls ( P Z 0.5). In the control group, one of the subjectsh ad levels of binary complex below the detectionl imit,a nd therefore, this person wase xcluded fromt he calculations. In the remainings ix subjects,t he T 1/2 of theb inaryc omplex averaged8 8 G 3min.T he T 1/2 of theb inaryc omplex averaged 148 G 29 mini nc irrhoticp atients.T he difference in T 1/2 of theb inaryc omplex wasn ot statisticallys ignificantb etween patients andc ontrols ( P Z 0.1).H owever,t he T 1/2 of theb inaryc omplex was significantlyshorterthanthatofIGFBP-1 in both controls (2.5G 0.2 times, P ! 0.0001) and cirrhotic patients (1.8G 0.3times, P ! 0.005).
Theserum concentrations of IGFBP-2did notchange significantlyduringthe OGTT in either cirrhoticpatients or healthycontrols (Fig. 2D) .
Discussion
The primaryaim of the present study wastoinvestigate the dynamic changesi nI GF-I (measuredi nf our different forms, i.e., total, free, bioactive, and IGFBP-1-bound IGF-I), as well as IGFBP-1 and IGFBP-2 during an oral glucose challenge in patients with liver cirrhosis. In accordancew ith previous studies (15) (16) (17) (18) , we confirmed that fasting serum concentrationso ft otal andf reeI GF-I were reduced and IGFBP-1 levels elevated,w hile IGF-I:IGFBP-1b inaryc omplex and IGFBP-2 tended to be higher in cirrhotic patients, as compared with healthycontrols. In addition,weshowed that thec irculatingb ioactivityo fI GF-I wasa lso subnormal in cirrhosis, and that levels, in contrast to totala nd free IGF-I, declined during the OGTT.T his observation mayb ee xplained by the higher levels of unsaturatedI GFBP-1 (i.e. 'freeI GFBP-1') and faster disappearance of IGFBP-1-bound IGF-I, whichm ay serve as as ource of 'readilyd issociable' and hence receptor-accessible IGF-I.
It is well known thatc irculatingI GFBP-1, due to its inverser elationship with insulin, becomes suppressed afteri ntake of meals and glucose (30) (31) (32) (33) (34) .F or this reason, serumI GFBP-1 hasb eene mployeda sa n estimate of b -cellf unction and insulin sensitivity in numerous clinical conditions, including liverc irrhosis (19, 35) .Inthe present study,baseline levels of IGFBP-1 were elevated moret hant wofoldi np atientsw ith cirrhosis as compared to healthys ubjects, in keeping with the cirrhosis-related insulin resistance (19, 25) . Nevertheless, following the 75 gg lucose load (90-180 min),c irrhotic patients showed the same relative suppression of IGFBP-1( 21-32%) as that observed in healthycontrols( 19-41%), while IGFBP-2 remained unchanged during the OGTT in both study groups.T hus,d espite ther educedh epatic insulin sensitivity resulting in higherb aseline levels,t he hepatocytes were able to respond 'normally' to an increased insulin exposure.
The originalI GF-I bioassayw as based on measurementofcultured costal cartilage uptakeofradio-labeled thymidine or sulfate. Later assays employed IGF-Iinduced proliferation of BALB/c 3T3 fibroblast cells or MCF-7 human mammary adenocarcinoma cells as an estimate of IGF-I bioactivity (36) (37) (38) (39) .A lthough the earlybioassays have contributedimportantinformation on factorsc ontrolling IGF-Ib ioactivity,t heyy ield relativelyu nspecifics ignals. Therefore, modernb ioassays detectingt he initial commitment of ac ell to respond (i.e. intracellular signals) following the ligand activation have been developed (40, 41) .T he IGF-I receptor belongs to the tyrosinek inase receptor superfamily ( 42, 43) .T he auto-phosphorylation of tyrosine residues aftert he stimulation of IGF-I receptor (ligand binding) is the first step of the intracellular signal cascade. Accordingly, we have recentlyd eveloped a highlys pecificI GF-I KIRA, whichh as enabled us to determine thea bility of serum to activate (i.e. phosphorylate) the IGF-I receptor in vitro (28) . This measurement is mostlikelycomposed of the sum of two moieties: free, unbound IGF-I and IGF-I being dissociated from the IGFBPs during incubation of serum with the IGF-I receptor gene-transfected cells. The latter, oftenr eferred to as 'readilydissociable IGF-I', has been suggestedt ob eb iologicallya ctive ( 44) .O ur recent studies have supported this hypothesis indirectly, since the level of bioactiveIGF-I measured by the IGF-I KIRA has been higher than thatoffree IGF-I, but lower than totalIGF-I (28, 45) .
In thep resent study, theI GF-I bioactivityw as significantlylower in cirrhotic patientsthaninhealthy subjects. This observation is in accordance with old findings ( 46, 47) . Furthermore,s erum total IGF-I remained unchanged during the OGTT and the same wast ruef or free IGF-I, despite the decrease in IGFBP-1 and rather stable IGFBP-2. Previous studies from our laboratory, as well as from others, have uniformlyshown thatserum-free IGF-I determined by either ultrafiltration or ac ommercial IRMA remains unchanged after oral glucose, as well as aftermeal intake (48) .Ont he other hand, levels of bioactiveIGF-I decreased significantlyin cirrhotic patients and the samet endency wasa lso observed in healthyc ontrols during the OGTT ( P Z 0.052). This finding argues against the observation by Bereket and co-workers( 49), which indicated thati n response to food (or glucose) intake, changes in IGFBP-1 concentrations within the physiological range would not sufficientlya ffect IGF-Ib ioactivity by limitingt he availability of free IGF-I.
We have previously suggestedt hatt he IGFBP-1 saturation index reflects the fraction of IGFBP-1 being saturated with IGF-I (9).I nk eeping with this, al ow IGFBP-1 saturation index implies thatl ess IGFBP-1 is boundt oI GF-I, i.e. more IGFBP-1i sp resent as unsaturated'free IGFBP-1'.Since IGFBP-1 has astrong inhibitoryeffect on IGF-I bioactivity (1, 9),wespeculate thatd uring the OGTT,t he gradual decreasei nt he IGFBP-1 saturation index, which equals an increase in the fraction of unsaturated IGFBP-1, maycontribute to the reduction in bioactiveI GF-I observedi nt he later parto fthe present experiment. However, the reduction in bioactiveI GF-I during the OGTT mayalso reflect an increased trans-capillaryt ransport of IGF-I bound to IGFBP-1 (please see below).
Although the present study wasn ot designed to determine the half-lives of IGFBP-1 and the binary complex, the time-concentrationc urvesi mplied that aftert he oral glucose load the disappearance of the binarycomplex wasfaster than thatofIGFBP-1. Indeed, this wasc onfirmed by the estimated half-lives, which showed that during the 180 min of study,the clearance of theb inaryc omplex was approximatelyt wofold shorter thanthatofI GFBP-1.
Whether the faster clearance of IGF-I:IGFBP-1binary complex is due to an increased degradation or an accelerated trans-capillarytransport to the extravascular compartment remains to be determined.Atthe time of writing, therew ereo nlys parsed atao nt he mechanismsc ontrolling the trans-capillaryt ransport of the circulating IGF-system.P ayet et al. (50) did not observeany effect of radio-labeled IGF-I on the transport of IGFBP-3 and IGFBP-5 across the cultured human umbilicalv ein endothelialm onolayer.T hisw as in agreementw ith findings by Lewitt et al.( 51) ,w ho showed that in rats, the half-lifei nt he serum of intravenously injectedh uman IGFBP-1 wasn ot influenced by co-administration of IGF-I. In contrast, we have indirect in vivo evidence supporting that in humans, IGFBP-1 mayb ec leared morer apidlyi nt he presence of IGF-I. In an earlier study,h ealthys ubjects received 3d ayso fs .c.i nfusiono fe ither saline or IGF-I (10 m g/kg/h),after whicha300-min hyperinsulinemic clampw as performed. After 3d ayso fs aline infusion, the hyperinsulinemic clampr educed IGFBP-1 by about twofold. In comparison, after 3d ayso fI GF-I infusion, when all IGFBPs were likelyt ob ef ullys aturated with IGF-I, the hyperinsulinemic clamp reduced IGFBP-1 by about fourfold ( 52) . However,w ea cknowledget hat furthers tudiesa re required to confirmt hatt he clearance of IGFBP-1 is dependent on IGF-I binding.
Cirrhotic patients were characterized by an abnormal glucose metabolism, whicha ppearst ob ec aused by insulin resistance in peripheral tissues (25) .W ebelieve these characteristic features are linked pathophysiologicallytolow levels of bioactiveIGF-I. Accordingly, there is strong experimental evidence thatl ow levels of circulatingIGF-I result in peripheral insulin resistance. Thisappearstob emediated through twomechanisms: first, an inadequate IGF-I-mediated negative feedback at thel evel of theh ypothalamus/pituitaryl eading to chronic GH hypersecretiona nd secondly, IGF-I has been suggestedt oe xert ad irect stimulating effect on insulin sensitivity in skeletal muscles (53) .However,we acknowledgethatthese hypotheses remain to be tested.
In conclusion, we show that patients with liver cirrhosiss ufferf rom markedlys uppressedl evels of bioactive IGF-I. Furthermore,w ed emonstrate that despite relativelyunchanged circulating concentrations of total and free IGF-I, bioactive IGF-Id eclines significantlyafteranoral glucose load.W eh ypothesize thatt he reduction in bioactiveI GF-I during the OGTT mayb ec aused by the higher levels of unsaturated IGFBP-1 as well as the faster disappearance of 'readily dissociableI GF-I'p resent in IGF-I:IGFBP-1 binary complexes. Furthermore,o ur data implyt hat the clearance of IGFBP-1 mayd epend on its bindingt o IGF-I. However,t his needs further investigation.
